| Direct oral anticoagulant considerations in solid organ transplantation: a review DM Salerno, D Tsapepas, A Papachristos, JH Chang, S Martin, MA Hardy, ... Clinical transplantation 31 (1), e12873, 2017 | 48 | 2017 |
| The urinary microbiome and bladder cancer: susceptibility and immune responsiveness C Andolfi, JC Bloodworth, A Papachristos, RF Sweis Bladder Cancer 6 (3), 225-235, 2020 | 29 | 2020 |
| Correlation between bevacizumab exposure and survival in patients with metastatic colorectal cancer A Papachristos, P Kemos, H Kalofonos, G Sivolapenko The Oncologist 25 (10), 853-858, 2020 | 26 | 2020 |
| Personalizing chemotherapy dosing using pharmacological methods JN Patel, A Papachristos Cancer chemotherapy and pharmacology 76, 879-896, 2015 | 26 | 2015 |
| Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines A Papachristos, N Pippa, C Demetzos, G Sivolapenko Drug delivery 23 (5), 1662-1666, 2016 | 24 | 2016 |
| VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer A Papachristos, P Kemos, T Katsila, E Panoilia, GP Patrinos, H Kalofonos, ... International journal of molecular sciences 20 (22), 5791, 2019 | 23 | 2019 |
| Do we need to adopt antifungal stewardship programmes? K Ioannidis, A Papachristos, I Skarlatinis, F Kiospe, S Sotiriou, ... European Journal of Hospital Pharmacy 27 (1), 14-18, 2020 | 18 | 2020 |
| Pharmacogenomics, pharmacokinetics and circulating proteins as biomarkers for bevacizumab treatment optimization in patients with cancer: a review A Papachristos, GB Sivolapenko Journal of Personalized Medicine 10 (3), 79, 2020 | 12 | 2020 |
| Pharmacogenetics in model-based optimization of bevacizumab therapy for metastatic colorectal cancer A Papachristos, E Karatza, H Kalofonos, G Sivolapenko International Journal of Molecular Sciences 21 (11), 3753, 2020 | 10 | 2020 |
| Dose optimization in oncology drug development: the emerging role of pharmacogenomics, pharmacokinetics, and pharmacodynamics A Papachristos, J Patel, M Vasileiou, GP Patrinos Cancers 15 (12), 3233, 2023 | 8 | 2023 |
| Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives A Papachristos, N Pippa, K Ioannidis, G Sivolapenko, C Demetzos Journal of liposome research 25 (2), 166-173, 2015 | 8 | 2015 |
| Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab. A Papachristos, MJ Ratain Clinical Pharmacology & Therapeutics 110 (1), 2021 | 6 | 2021 |
| Machine learning‐guided covariate selection for time‐to‐event models developed from a small sample of real‐world patients receiving bevacizumab treatment E Karatza, A Papachristos, GB Sivolapenko, D Gonzalez CPT: Pharmacometrics & Systems Pharmacology 11 (10), 1328-1340, 2022 | 4 | 2022 |
| Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development JD Davis, M Bravo Padros, DJ Conrado, S Ganguly, X Guan, HE Hassan, ... Clinical Pharmacology & Therapeutics 115 (3), 422-439, 2024 | 3 | 2024 |
| Concentration-related mydriasis in a patient with renal dysfunction treated with phenytoin K Ioannidis, A Papachristos, Z Athanassa, I Skarlatinis, H Paskalis Hippokratia 20 (2), 166, 2016 | 2 | 2016 |
| 127P Personalizing treatment in colorectal cancer by monitoring bevacizumab blood levels and ICAM-1 polymorphisms A Papachristos, E Karatza, H Kalofonos, G Sivolapenko Annals of Oncology 31, S290-S291, 2020 | 1 | 2020 |
| 4CPS-077 Do we need to adopt antifungal stewardship programmes? K Ioannidis, I Scarlatinis, A Papachristos, F Kiospe, S Sotiriou, ... European Journal of Hospital Pharmacy 25 (Suppl 1), A77-A78, 2018 | 1 | 2018 |
| Drug utilization patterns and costs of erythropoiesis-stimulating agents in an outpatient setting in Greece A Papachristos, C Kani, P Litsa, G Valsami, K Souliotis, M Saridi, ... The Consultant Pharmacist® 31 (5), 271-281, 2016 | 1 | 2016 |
| Safety and effectiveness of the combination acetazolamide and bicarbonates to induce alkaline diuresis in patients with rhabdomyolysis K Ioannidis, A Papachristos, Z Athanassa, E Katsouda, I Skarlatinis, ... European Journal of Hospital Pharmacy 22 (6), 328-332, 2015 | 1 | 2015 |
| High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma D Rischin, BGM Hughes, N Basset-Séguin, D Schadendorf, S Bowyer, ... Journal for immunotherapy of cancer 12 (3), 2024 | | 2024 |
Gregory SivolapenkoAssoc Professor of Pharmacy, University of Patras, Patras, Greece在 upatras.gr 的电子邮件经过验证
